These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15912959)

  • 1. The potential use of PPARalpha agonists as immunosuppressive agents.
    Cunard R
    Curr Opin Investig Drugs; 2005 May; 6(5):467-72. PubMed ID: 15912959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrates upregulate TRB3 in lymphocytes independent of PPAR alpha by augmenting CCAAT/enhancer-binding protein beta (C/EBP beta) expression.
    Selim E; Frkanec JT; Cunard R
    Mol Immunol; 2007 Feb; 44(6):1218-29. PubMed ID: 16949670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
    Chinetti-Gbaguidi G; Fruchart JC; Staels B
    Biomarkers; 2005 Nov; 10 Suppl 1():S30-6. PubMed ID: 16298909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fibrates and markers of inflammation].
    Broncel M
    Pol Merkur Lekarski; 2007 Jan; 22(127):58-61. PubMed ID: 17477093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
    Pinelli A; Godio C; Laghezza A; Mitro N; Fracchiolla G; Tortorella V; Lavecchia A; Novellino E; Fruchart JC; Staels B; Crestani M; Loiodice F
    J Med Chem; 2005 Aug; 48(17):5509-19. PubMed ID: 16107150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes.
    Nakamachi T; Nomiyama T; Gizard F; Heywood EB; Jones KL; Zhao Y; Fuentes L; Takebayashi K; Aso Y; Staels B; Inukai T; Bruemmer D
    Diabetes; 2007 Jun; 56(6):1662-70. PubMed ID: 17360982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in research on peroxisome proliferator-activated receptor alpha-selective ligands.
    Miyachi H
    IDrugs; 2004 Aug; 7(8):746-54. PubMed ID: 15334308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B; Maes M; Zambon A
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential antiatherogenic effects of PPARalpha versus PPARgamma agonists: should we be surprised?
    Camejo G
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1763-4. PubMed ID: 16127025
    [No Abstract]   [Full Text] [Related]  

  • 11. Factors modulating fibrates response: therapeutic implications and alternative strategies.
    Panadero MI; González MC; Herrera E; Bocos C
    Endocr Metab Immune Disord Drug Targets; 2009 Sep; 9(3):219-36. PubMed ID: 19594420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence.
    Zambon A; Gervois P; Pauletto P; Fruchart JC; Staels B
    Arterioscler Thromb Vasc Biol; 2006 May; 26(5):977-86. PubMed ID: 16424352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists down-regulate alpha2-macroglobulin expression by a PPARalpha-dependent mechanism.
    González MC; Corton JC; Cattley RC; Herrera E; Bocos C
    Biochimie; 2009 Aug; 91(8):1029-35. PubMed ID: 19497347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1.
    Grau R; Punzón C; Fresno M; Iñiguez MA
    Biochem J; 2006 Apr; 395(1):81-8. PubMed ID: 16343055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Babaev VR; Ishiguro H; Ding L; Yancey PG; Dove DE; Kovacs WJ; Semenkovich CF; Fazio S; Linton MF
    Circulation; 2007 Sep; 116(12):1404-12. PubMed ID: 17724261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
    Fracchiolla G; Laghezza A; Piemontese L; Tortorella P; Mazza F; Montanari R; Pochetti G; Lavecchia A; Novellino E; Pierno S; Conte Camerino D; Loiodice F
    J Med Chem; 2009 Oct; 52(20):6382-93. PubMed ID: 19775169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrate therapy: an update.
    Remick J; Weintraub H; Setton R; Offenbacher J; Fisher E; Schwartzbard A
    Cardiol Rev; 2008; 16(3):129-41. PubMed ID: 18414184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
    Matin A; Gavande N; Kim MS; Yang NX; Salam NK; Hanrahan JR; Roubin RH; Hibbs DE
    J Med Chem; 2009 Nov; 52(21):6835-50. PubMed ID: 19807106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPARalpha ligands cause lymphocyte depletion and cell cycle block and this is associated with augmented TRB3 and reduced Cyclin B1 expression.
    Morse E; Selim E; Cunard R
    Mol Immunol; 2009 Oct; 46(16):3454-61. PubMed ID: 19748123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
    Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK
    Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.